Diethylcarbamazine Attenuates the Development of Carrageenan-Induced Lung Injury in Mice

• Main Authors: Edlene Lima Ribeiro (Author), Karla Patricia de Souza Barbosa (Author), Ingrid Tavares Fragoso (Author), Mariana Aragão Matos Donato (Author), Fabiana Oliveira dos Santos Gomes (Author), Bruna Santos da Silva (Author), Amanda Karolina Soares e Silva (Author), Sura Wanessa Santos Rocha (Author), Valdemiro Amaro da Silva Junior (Author), Christina Alves Peixoto (Author)
• Format: Book
• Published: Hindawi Limited, 2014-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Diethylcarbamazine (DEC) is an antifilarial drug with potent anti-inflammatory properties as a result of its interference with the metabolism of arachidonic acid. The aim of the present study was to evaluate the anti-inflammatory activity of DEC in a mouse model of acute inflammation (carrageenan-induced pleurisy). The injection of carrageenan into the pleural cavity induced the accumulation of fluid containing a large number of polymorphonuclear cells (PMNs) as well as infiltration of PMNs in lung tissues and increased production of nitrite and tumor necrosis factor-α and increased expression of interleukin-1β, cyclooxygenase (COX-2), and inducible nitric oxide synthase. Carrageenan also induced the expression of nuclear factor-κB. The oral administration of DEC (50 mg/Kg) three days prior to the carrageenan challenge led to a significant reduction in all inflammation markers. The present findings demonstrate that DEC is a potential drug for the treatment of acute lung inflammation.

Item Description

0962-9351
1466-1861
10.1155/2014/105120